Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $70.2 million.

  • SAB Biotherapeutics' Non-Current Assets rose 23006.18% to $70.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.2 million, marking a year-over-year increase of 4320.74%. This contributed to the annual value of $20.4 million for FY2024, which is 1849.92% down from last year.
  • As of Q3 2025, SAB Biotherapeutics' Non-Current Assets stood at $70.2 million, which was up 23006.18% from $20.8 million recorded in Q2 2025.
  • SAB Biotherapeutics' Non-Current Assets' 5-year high stood at $116.2 million during Q3 2021, with a 5-year trough of $20.4 million in Q4 2024.
  • Its 5-year average for Non-Current Assets is $42.5 million, with a median of $27.6 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first crashed by 7389.3% in 2022, then skyrocketed by 23006.18% in 2025.
  • Over the past 5 years, SAB Biotherapeutics' Non-Current Assets (Quarter) stood at $30.9 million in 2021, then fell by 6.92% to $28.8 million in 2022, then dropped by 13.1% to $25.0 million in 2023, then decreased by 18.5% to $20.4 million in 2024, then skyrocketed by 243.92% to $70.2 million in 2025.
  • Its last three reported values are $70.2 million in Q3 2025, $20.8 million for Q2 2025, and $21.8 million during Q1 2025.